Breaking News Instant updates and real-time market news.

GWPH

GW Pharmaceuticals

$123.98

1.66 (1.36%)

04:57
12/14/17
12/14
04:57
12/14/17
04:57

GW Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs

Goldman Sachs analyst Salveen Richter upgraded GW Pharmaceuticals to Buy and raised his price target for the shares to $174 from $124. The British biopharmaceutical company closed yesterday up $1.66 to $123.98. Recent clobazam drug-drug interaction data showing independent and synergistic Epidiolex activity addresses a key investor concern, Richter tells investors in a research note. The analyst's checks with key opinion leaders indicate substantial interest in Epidiolex adoption and off-label use in children and adults, which he believes bodes well for the launch. He models for 2025 worldwide peak sales of $2.2B and sees multiple pipeline catalysts in 2018.

GWPH GW Pharmaceuticals
$123.98

1.66 (1.36%)

10/03/17
MZHO
10/03/17
NO CHANGE
Target $51
MZHO
Buy
Zogenix price target raised to $51 from $28 at Mizuho
Mizuho analyst Difei Yang raised his price target for Zogenix (ZGNX) to $51 from $28 after it announced positive topline data for its pivotal phase III trial of ZX008 in Dravet Syndrome - Study 1. The analyst notes study 1 met its primary endpoint, with topline results indicating a clear dose response, efficacy appears better than GW Pharma's (GWPH) Epidiolex, and mechanism of action involving Sig-1R receptor could explain the higher specificity of ZX-008. Yang argues that these findings may allow ZX-008 to be positioned before Epidiolex as a treatment option for Dravet Syndrome patients. He reiterates a Buy rating on Zogenix's shares.
11/20/17
STFL
11/20/17
NO CHANGE
Target $55
STFL
Buy
Physicians expressed excitement for Zogenix epilepsy treatment, says Stifel
After hosting a panel to discuss new developments for rare epileptic conditions, Stifel analyst Annabel Samimy noted that physicians in the space said they believed there was a place for both Zogenix's (ZGNX) fenfluramine and GW Pharmaceuticals' (GWPH) Epidiolex, the two most advanced treatments for Dravet Syndrome and Lennox-Gastaut Syndrome. Excitement for their introductions was "palpable, particularly for fenfluramine," added Samimy, who has a Buy rating and $55 price target on Zogenix and does not cover GW Pharmaceuticals.
11/21/17
CANT
11/21/17
NO CHANGE
Target $208
CANT
Overweight
Abstracts put GW's drug-drug interaction issue to rest, says Cantor
Cantor Fitzgerald analyst Elemer Piros says the American Epilepsy Society published last night 20 abstracts detailing the safety/efficacy of GW Pharmaceuticals' Epidiolex in a multitude of controlled trials and refractory epilepsy indications. GW and collaborators "finally laid the somewhat common concern to rest: does the drug work partly or solely due to a boosting effect on another anti-epileptic drug commonly used, Clobazam?" Piros tells investors in a research note. He believes the answer is "partly." The bear thesis of Epidiolex working "solely" through boosting Clobazam's efficacy has been qualitatively debunked by management before, and now there are numbers to back it up, the analyst adds. He expects a potential approval for Epidiolex in April 2018. Piros has an Overweight rating on GW Pharmaceuticals with a $208 price target. The stock in premarket trading is up $5.23 to $120.00.
12/05/17
CANT
12/05/17
NO CHANGE
Target $208
CANT
Overweight
GW shares still 'significantly undervalued,' says Cantor Fitzgerald
Following the company's fiscal 2017 results, Cantor Fitzgerald analyst Elemer Piros says shares of GW Pharmaceuticals remain "significantly undervalued" based on Epidiolex's opportunity in treating orphan pediatric epileptic conditions. The analyst notes that before the end of 2017, the FDA will announce whether GW's New Drug Application filing has been accepted for review. Piros keeps an Overweight rating on the shares with a $208 price target.

TODAY'S FREE FLY STORIES

TSS

TSYS

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Initiation
TSYS initiated  »

TSYS initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

RARE

Ultragenyx

$84.32

-0.23 (-0.27%)

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Recommendations
Ultragenyx analyst commentary  »

Ultragenyx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

KTOS

Kratos Defense

$12.85

0.14 (1.10%)

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Hot Stocks
Kratos Defense receives $8.5M in orders in support of C5 programs »

Kratos Defense announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$81.97

0.26 (0.32%)

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Initiation
Cognizant initiated  »

Cognizant initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 15

    Aug

  • 16

    Aug

LTC

LTC Properties

$41.84

-0.32 (-0.76%)

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Hot Stocks
LTC Properties acquires two communities for $25.2M »

LTC Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WP

Worldpay

$86.51

(0.00%)

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Initiation
Worldpay initiated  »

Worldpay initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

FDC

First Data

$22.24

-0.06 (-0.27%)

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Initiation
First Data initiated  »

First Data initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

BR

Broadridge

$117.70

-0.27 (-0.23%)

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Initiation
Broadridge initiated  »

Broadridge initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$138.45

-0.91 (-0.65%)

09:30
07/17/18
07/17
09:30
07/17/18
09:30
Initiation
Visa initiated  »

Visa initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

FIVE

Five Below

$103.50

2.1 (2.07%)

09:30
07/17/18
07/17
09:30
07/17/18
09:30
Recommendations
Five Below analyst commentary  »

Five Below price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MA

MasterCard

$204.05

-1.86 (-0.90%)

09:30
07/17/18
07/17
09:30
07/17/18
09:30
Initiation
MasterCard initiated  »

MasterCard initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

UNH

UnitedHealth

$257.03

-1.69 (-0.65%)

09:30
07/17/18
07/17
09:30
07/17/18
09:30
Hot Stocks
Breaking Hot Stocks news story on UnitedHealth »

UnitedHealth sees 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

PYPL

PayPal

$87.77

-0.2 (-0.23%)

09:30
07/17/18
07/17
09:30
07/17/18
09:30
Initiation
PayPal initiated  »

PayPal initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 16

    Aug

SBRA

Sabra Health Care

$22.36

-0.17 (-0.75%)

09:28
07/17/18
07/17
09:28
07/17/18
09:28
Hot Stocks
Sabra, PointRight announce strategic partnership for post-acute analytics »

Sabra Health Care REIT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECOR

ElectroCore

$14.49

-0.51 (-3.40%)

09:28
07/17/18
07/17
09:28
07/17/18
09:28
Initiation
ElectroCore initiated  »

ElectroCore initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRC

Hill-Rom

$91.35

0.03 (0.03%)

09:28
07/17/18
07/17
09:28
07/17/18
09:28
Recommendations
Hill-Rom analyst commentary  »

Hill-Rom price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

  • 15

    Aug

PM

Philip Morris

$81.91

-0.78 (-0.94%)

09:26
07/17/18
07/17
09:26
07/17/18
09:26
Recommendations
Philip Morris analyst commentary  »

Philip Morris estimates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

NFLX

Netflix

$400.24

4.32 (1.09%)

09:25
07/17/18
07/17
09:25
07/17/18
09:25
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:25
07/17/18
07/17
09:25
07/17/18
09:25
General news
U.S. industrial production bounced 0.6% in June »

U.S. industrial…

09:25
07/17/18
07/17
09:25
07/17/18
09:25
General news
FX Action: The dollar »

FX Action: The dollar was…

09:25
07/17/18
07/17
09:25
07/17/18
09:25
Conference/Events
Stifel maritime analysts to hold an analyst/industry conference call »

Maritime Analysts, hosts…

MSI

Motorola Solutions

$121.33

0.54 (0.45%)

09:22
07/17/18
07/17
09:22
07/17/18
09:22
Hot Stocks
Motorola Solutions wins patent infringement lawsuit against Hytera Mobilfunk »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$23.00

2.11 (10.10%)

09:21
07/17/18
07/17
09:21
07/17/18
09:21
Initiation
Autolus Therapeutics initiated  »

William Blair starts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$124.70

-1.24 (-0.98%)

09:20
07/17/18
07/17
09:20
07/17/18
09:20
Hot Stocks
Breaking Hot Stocks news story on Johnson & Johnson »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 08

    Aug

LULU

Lululemon

$127.21

1.8 (1.44%)

09:19
07/17/18
07/17
09:19
07/17/18
09:19
Recommendations
Lululemon analyst commentary  »

Lululemon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 19

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.